Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for aggressive brain lymphoma: 3-drug combo enters phase 2 trial

NCT ID NCT07523737

Recruiting now Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated May 16, 2026 · Updated 5 times

Summary

This study tests a combination of three drugs (pomalidomide, an anti-PD-1 antibody, and selinexor) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if this combination can shrink or eliminate tumors. About 43 adults aged 18 to 75 will take part. The approach aims to control the disease rather than cure it, as ongoing management is expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tongren Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)